

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AI Health Technology Limited

智慧健康科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1715)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of AI Health Technology Limited (the “**Company**”) announces that, with effect from 2 July 2026 (after trading hours), Ms. Wang Jian (“**Ms. Wang**”) has been appointed as an executive Director.

The biographical details of Ms. Wang are set out as follows:

Ms. Wang, aged 47, graduated from the Central University of Finance and Economics* (中央財經大學) with a Master of Business Administration degree in 2018.

Ms. Wang served as the design director at Beijing Greenstone Decoration Design Co., Ltd.* (北京格林貝石裝飾設計有限公司) from June 2009 to December 2014, where she was primarily responsible for providing clients with architectural and interior design services. From March 2015 to December 2023, she served as the chairman and a general manager of Beijing Zhongjian Huahao Construction Engineering Co., Ltd.* (北京中建華昊建築工程有限公司), where she was responsible for overall management and business development planning. From May 2018 to November 2019, she also served as the managing director of Guojian Health City (Beijing) Technology Development Co., Ltd.* (國健健康城(北京)技術開發有限公司), a company primarily engaged in investment in the health industry and the construction of health and wellness parks. Since November 2019, she has been serving as a general manager of Beijing Diwoke Cultural Creativity Co., Ltd.* (北京迪沃客文化創意有限公司), a company primarily providing architectural design and art industry-related services, and offering investment and incubation platforms for high-potential projects.

In addition, Ms. Wang currently serves as the Secretary-General of the Food and Drug Health Working Committee of the China National Association of Traditional Chinese Medicine* (中國民族醫藥協會食藥健康工作委員會).

Ms. Wang has entered into a service agreement with the Company on 2 July 2026 for a term of one year commencing from 2 July 2026 to 1 July 2027, unless terminated by either party giving three months' prior written notice. Ms. Wang is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the memorandum and articles of association of the Company. Ms. Wang is entitled to an annual remuneration of HK\$120,000, which was determined by the Board with reference to the recommendations from the remuneration committee of the Board, after taking into account, among other things, her responsibilities and the prevailing market terms.

As at the date of this announcement and save as disclosed above, (i) Ms. Wang has not held any directorships in public companies the securities of which are listed in Hong Kong or overseas in the last three years; (ii) Ms. Wang has not held any other positions in the Company or any of its subsidiaries; (iii) Ms. Wang does not have any relationship with any other directors, senior management, substantial or controlling shareholders of the Company; (iv) Ms. Wang does not have any other interest in the listed securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance; and (v) there is no information relating to the appointment of Ms. Wang that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) or any other matter concerning Ms. Wang's appointment that needs to be brought to the attention of the shareholders of the Company.

Prior to his appointment, Ms. Wang has obtained legal advice as regards to the requirements under the Listing Rules that are applicable to her as a director of a listed issuer. Ms. Wang fully understands her duties and obligations as a Director under the Listing Rules and the possible consequences of making a false declaration or giving false information to The Stock Exchange of Hong Kong Limited.

The Board would like to express its warmest welcome to Ms. Wang for joining the Board.

By order of the Board
AI Health Technology Limited
Zhao Jie
Executive Director

Hong Kong, 2 July 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Zhao Jie, Madam Maeck Can Yue and Ms. Wang Jian, and the independent non-executive Directors of the Company are Mr. Lin Dongming, Mr. Shen Shujing and Ms. Zhang Yuanjie.

* *For identification purposes only*